These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
118 related articles for article (PubMed ID: 2128854)
1. Preclinical characterization of a new pasteurized monoclonal antibody purified factor VIIIC. Hrinda ME; Feldman F; Schreiber AB Semin Hematol; 1990 Apr; 27(2 Suppl 2):19-24. PubMed ID: 2128854 [TBL] [Abstract][Full Text] [Related]
2. Initial clinical experience with a new pasteurized monoclonal antibody purified factor VIIIC. Smith KJ; Lusher JM; Cohen AR; Salzman P Semin Hematol; 1990 Apr; 27(2 Suppl 2):25-9. PubMed ID: 2128855 [TBL] [Abstract][Full Text] [Related]
3. Human factor VIII:C purified using monoclonal antibody to von Willebrand factor. Levine PH Semin Hematol; 1988 Apr; 25(2 Suppl 1):1-2. PubMed ID: 3133770 [No Abstract] [Full Text] [Related]
4. [Properties of factor VIII/von Willebrand factor in two highly-purified factor VIII concentrates, Hemofil M and Monoclate, using monoclonal antibodies]. Tanaka I; Yoshioka A; Shima M; Fujiwara T; Terada S; Nakai H; Miyata S; Sawamoto Y; Kamisue S; Fukui H Rinsho Ketsueki; 1989 Jul; 30(7):951-7. PubMed ID: 2509762 [TBL] [Abstract][Full Text] [Related]
5. Ultracentrifugal analysis of factor VIII and von Willebrand factor in therapeutic preparations. Aronson DL; Chang P Vox Sang; 1995; 69(1):8-13. PubMed ID: 7483501 [TBL] [Abstract][Full Text] [Related]
6. Viral safety and inhibitor development associated with factor VIIIC ultra-purified from plasma in hemophiliacs previously unexposed to factor VIIIC concentrates. The Monoclate Study Group. Lusher JM; Salzman PM Semin Hematol; 1990 Apr; 27(2 Suppl 2):1-7. PubMed ID: 1965615 [TBL] [Abstract][Full Text] [Related]
7. Biochemical properties of Monoclate factor VIII:C antihemophilic factor (human) using monoclonal antibody to von Willebrand factor (VWF). Nilsson IM Semin Hematol; 1988 Apr; 25(2 Suppl 1):33-7. PubMed ID: 3133776 [No Abstract] [Full Text] [Related]
8. Viral safety of a pasteurized, monoclonal antibody-purified factor VIII concentrate in previously untreated haemophilia A patients. Philipp CS; Haemophilia; 2001 Mar; 7(2):146-53. PubMed ID: 11260273 [TBL] [Abstract][Full Text] [Related]
9. Immunoaffinity purification of factor VIII. Weinstein RE Ann Clin Lab Sci; 1989; 19(2):84-91. PubMed ID: 2502062 [TBL] [Abstract][Full Text] [Related]
10. Adverse events reported in association with the use of monoclonal antibody purified factor VIIIC--Monoclate. Brown DC Semin Hematol; 1990 Apr; 27(2 Suppl 2):16-7; discussion 18. PubMed ID: 2128853 [TBL] [Abstract][Full Text] [Related]
11. Biochemical and in vivo properties of commercial virus-inactivated factor VIII concentrates. Berntorp E; Nilsson IM Eur J Haematol; 1988 Mar; 40(3):205-14. PubMed ID: 3128452 [TBL] [Abstract][Full Text] [Related]
12. Viral safety and inhibitor development associated with monoclonal antibody-purified F VIII C. Lusher JM Ann Hematol; 1991 Sep; 63(3):138-41. PubMed ID: 1932288 [No Abstract] [Full Text] [Related]
13. [Improvement in anti-hemophilic preparations and its problems. 4. Factor VIII preparation (RCG-5) with intermediate purity and potency]. Yoshioka A Rinsho Ketsueki; 1988 May; 29(5):649-54. PubMed ID: 3145996 [No Abstract] [Full Text] [Related]
14. In vivo recovery and survival of monoclonal-antibody-purified factor VIII concentrates. Kasper CK; Kim HC; Gomperts ED; Smith KJ; Salzman PM; Tipping D; Miller R; Montgomery RM Thromb Haemost; 1991 Dec; 66(6):730-3. PubMed ID: 1796419 [TBL] [Abstract][Full Text] [Related]
15. Pasteurized, monoclonal antibody factor VIII concentrate: establishing a new standard for purity and viral safety of plasma-derived concentrates. Goldsmith JC Blood Coagul Fibrinolysis; 2000 Mar; 11(2):203-15. PubMed ID: 10759015 [TBL] [Abstract][Full Text] [Related]
16. Continuous infusion of monoclonal antibody-purified factor VIII. Weinstein RE; Bona RD; Rickles FR Am J Hematol; 1991 Mar; 36(3):211-2. PubMed ID: 1899966 [TBL] [Abstract][Full Text] [Related]
17. Lack of immune response to mouse IgG in hemophilia A patients treated chronically with Monoclate, a monoclonal antibody affinity purified factor VIII preparation. Davis HM; Brown SK; Nash DW; Pennetti AM; Salzman PM; Schreiber AB; Haimovich J Thromb Haemost; 1990 Jun; 63(3):386-91. PubMed ID: 2119524 [TBL] [Abstract][Full Text] [Related]
18. Human anti-mouse immunoglobulins in sera of patients treated chronically with monoclonal antibody-purified factor VIII. Haimovich J; Davis HM; Schreiber AB Semin Hematol; 1990 Apr; 27(2 Suppl 2):11-5. PubMed ID: 2128852 [TBL] [Abstract][Full Text] [Related]
19. Protein content and factor VIII complex in untreated, treated and monoclonal factor VIII concentrates. Morfini M; Rafanelli D; Filimberti E; Cinotti S; Piazza E; Longo G; Rossi Ferrini P Thromb Res; 1989 Oct; 56(2):169-78. PubMed ID: 2515605 [TBL] [Abstract][Full Text] [Related]
20. Characterization of highly purified factor VIII products. Beeser H Ann Hematol; 1991 Sep; 63(3):126-30. PubMed ID: 1657208 [No Abstract] [Full Text] [Related] [Next] [New Search]